Search Results
Your search for Matthew Stenger,Matthew Stenger matches 7636 pages
Showing 151 - 200Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...
Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer
As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study showed no significant differences in progression-free or overall survival with first-line lenvatinib/pembrolizumab vs chemotherapy in patients with...
Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer
In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-free survival vs continuation of first-line oxaliplatin-based chemotherapy in patients with advanced...
MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML
As reported in the Journal of Clinical Oncology by Russell et al, the NCRI AML18 trial has shown survival benefit with treatment intensification in fit older patients with measurable residual disease (MRD)-positive response after first induction for acute myeloid leukemia (AML). Study Details In...
Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin
As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III...
Prognostic Factors in Limited-Stage SCLC Treated With Escalated Radiotherapy Doses
In a study reported in JAMA Network Open, Farris et al identified prognostic factors in patients with limited-stage small cell lung cancer (SCLC) receiving radiotherapy at two dose schedules in the CALGB 30610–RTOG 0538 trial. Study Details In the trial, 638 patients were randomly assigned between...
Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1–Associated Plexiform Neurofibroma
In a phase IIb trial (ReNeu) reported in the Journal of Clinical Oncology, Moertel et al found that the CNS-penetrant small molecule MEK1/2 inhibitor mirdametinib showed activity in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN). Study...
Glofitamab or Rituximab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory DLBCL
As reported in The Lancet by Abramson et al, the phase III STARGLO trial has shown significantly improved overall survival with glofitamab plus gemcitabine/oxaliplatin vs rituximab plus gemcitabine/oxaliplatin in patients with transplant-ineligible relapsed or refractory diffuse large B-cell...
Effect of Myeloma Therapy in a Patient With Monoclonal Gammopathy of Thrombotic Significance
In a letter to the editor in The New England Journal of Medicine, Salmasi et al described identification of monoclonal gammopathy of thrombotic significance (MGTS) in a patient with coronary artery disease and its successful treatment with daratumumab, bortezomib, and dexamethasone (DVd). As...
Nodal Burden and Recurrence in Patients With Breast Cancer With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy
In a retrospective study (OPBC-05/ICARO) reported in the Journal of Clinical Oncology, Giacomo Montagna, MD, MPH, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that nodal burden in patients with breast cancer with residual isolated tumor cells after neoadjuvant...
Novel Hypofractionated Proton-Beam Therapy for Older Patients With Newly Diagnosed Glioblastoma
In a phase II trial reported in The Lancet Oncology, Vora et al found that short-course hypofractionated proton-beam therapy guided by 3,4-dihydroxy-6-[F-18]fluoro-L-phenylalanine (F-18–DOPA) positron-emission tomography (PET) and contrast-enhanced MRI produced good outcomes in patients aged ≥ 65...
Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma
Hai-Qiang Mai, MD, of the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues reported their findings from a single-center phase II trial in The Lancet Oncology.1 They found that the addition of perioperative toripalimab to concurrent...
Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System
In a retrospective cohort study reported in The Lancet Oncology, Sean Miller, MD, of Veterans Affairs Ann Arbor Healthcare System, and colleagues found that immune checkpoint inhibitor treatment for cancer had similar efficacy and reduced toxicity in Black patients vs White patients in the U.S....
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
Georgina V. Long, PhD, MBBS, FRACP, of Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, and colleagues shared their findings from a pooled analysis of long-term outcomes in advanced melanoma reported in the Journal of Clinical Oncology.1 They found...
Performance of First-Line Chemotherapy Regimens in Unresectable Advanced or Metastatic Pancreatic Cancer
In a meta-analysis reported in The Lancet Oncology, Mastrantoni et al identified first-line chemotherapy regimens associated with better outcomes in patients with unresectable advanced or metastatic pancreatic cancer. Study Details The Bayesian network analysis included 79 randomized controlled...
Cancer-Specific Mortality Trends Among U.S. Asian and Pacific Islander Populations
In a study reported in JAMA Network Open, Zhu et al found that cancer-specific mortality rates have decreased overall among U.S. Asian and Pacific Islander populations during recent years, although increases in cancer-specific mortality have been reported for some cancers. Study Details The...
Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity
In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity. Study Details In the...
Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Ahn et al found the combination of the PLK1 inhibitor onvansertib with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab showed activity in the second-line treatment of KRAS-mutant metastatic colorectal cancer....
Enfortumab Vedotin in Previously Treated Advanced Head and Neck Cancer
In a phase II trial (EV-202) reported in the Journal of Clinical Oncology, Swiecicki et al found that the antibody-drug conjugate enfortumab vedotin showed activity in heavily pretreated patients with recurrent or metastatic head and neck cancer (HNC). Study Details In the study, 46 patients who...
Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma
In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation. Study Details In the double-blind Alliance for Clinical Trials...
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostatectomy radiotherapy vs those who did not, with little difference observed among patients with early ...
Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer
As reported in the Journal of Clinical Oncology by Jensen et al, the final analysis of the phase III Danish DBCG07-READ trial showed improved 10-year outcomes with the addition of epirubicin to docetaxel/cyclophosphamide adjuvant therapy in patients with TOP2A-normal breast cancer. The primary...
Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma
In a phase I study reported in The Lancet Oncology, Maruyama et al found that valemetostat—a novel dual inhibitor of EZH2 and EZH1—showed activity in patients with relapsed or refractory non-Hodgkin lymphoma. Study Details In the study, 90 patients from sites in Japan and the United States were...
Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis
In a single-institution study reported in JAMA Oncology, Cinciripini et al found that patients with cancer who quit smoking after a smoking cessation intervention had improved overall survival after cancer diagnosis. Study Details and Results The study involved data on 4,526 patients who were...
Addition of Inavolisib to Palbociclib/Fulvestrant in PIK3CA-Mutated Advanced Breast Cancer
In a phase III trial (INAVO120) reported in The New England Journal of Medicine, Nicholas C. Turner, MD, PhD, of Royal Marsden Hospital and the Institute of Cancer Research, London, and colleagues found that the addition of inavolisib to palbociclib/fulvestrant improved progression-free survival...
Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma
In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of nivolumab plus ipilimumab in patients with aggressive thyroid carcinoma. Study Details In the trial, 49 evaluable patients enrolled at Dana-Farber Cancer Institute between October 2017 and...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
In the phase III TULIP trial reported in the Journal of Clinical Oncology, Turner et al found that the third-generation HER2-targeted antibody-drug conjugate trastuzumab duocarmazine (T-Duo) improved progression-free survival vs physician's choice (PC) of treatment in patients with previously...
Risk of Ischemic Cardiotoxicity With Aromatase Inhibitors in Postmenopausal Patients With Early Breast Cancer
As reported in The Lancet Oncology by Lund et al, a Danish prospective cohort study showed no increased risk of ischemic cardiotoxicity with use vs no use of aromatase inhibitor treatment in postmenopausal patients with early-stage breast cancer. Study Details The study included identification of...
Addition of Atezolizumab Plus Bevacizumab to Chemotherapy in Advanced Biliary Tract Cancer
In a phase II trial (IMbrave151) reported in the Journal of Clinical Oncology, Macarulla et al found that atezolizumab/bevacizumab plus chemotherapy produced a “modest” improvement in progression-free survival vs atezolizumab/placebo plus chemotherapy in first-line treatment of patients with...
Next-Generation Oral SERD in Postmenopausal Women With ER-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (SERENA-2) reported in The Lancet Oncology, Oliveira et al found that the next-generation oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival vs fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, HER2-negative...
Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC
On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Supporting Efficacy...
Resection of Stage I to III Thymic Tumors in High-Volume U.S. Centers
In a study reported in a research letter in JAMA Surgery, Sakowitz et al found that R0 resection was more commonly achieved in patients with stage I to III thymic tumors who received surgery at high-volume centers (HVCs) for thymectomy in the United States. Study Details and Results The study...
Risk of Second Primary Cancers After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
In an English study reported in the Journal of Clinical Oncology, Allen et al found that patients with breast cancer harboring BRCA1/BRCA2 pathogenic variants were at high risk of second primary cancers. Study Details and Results The study involved follow-up of 25,811 females and 480 males...
Trends in Use of Primary Cytoreductive Surgery and Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer
In a study reported in a research letter in JAMA Network Open, Bercow et al found reduced use of primary cytoreductive surgery (PCS) and increased use of neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) in patients with advanced epithelial ovarian cancer during...
Prediction of Fracture Risk in Patients With Cancer
In a Canadian population–based cohort study reported in JAMA Oncology, Ye et al found that patients with cancer were at increased risk of fracture compared with individuals without cancer. In addition, a Fracture Risk Assessment Tool (FRAX) provided accurate prediction of this increased risk. As...
Valemetostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (VALENTINE-PTCL01) reported in The Lancet Oncology, Zinzani et al found that valemetostat—a novel dual inhibitor of EZH1 and EZH2—was active in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Study Details In the trial, 133 patients with relapsed or...
Inotuzumab Ozogamicin With Low-Intensity Chemotherapy in Older Patients With CD22-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL
In a phase II trial (EWALL-INO) reported in the Journal of Clinical Oncology, Chevallier et al found that inotuzumab ozogamicin combined with low-dose chemotherapy was active in the first-line treatment of older patients with newly diagnosed CD22-positive Philadelphia chromosome–negative B-cell...
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In a phase IIa study (DisTinGuish) reported in the Journal of Clinical Oncology, Klempner et al found that use of the DKK1-neutralizing antibody DKN-01 in combination with tislelizumab and chemotherapy showed activity in the first-line treatment of patients with advanced gastric or gastroesophageal ...
CDK4/6 Inhibition in Peritoneal Mucinous Carcinomatosis With GNAS Mutation
In a single-institution study reported in the Journal of Clinical Oncology, Weitz et al found that the CDK4/6 inhibitor palbociclib was active as a novel treatment in patients with peritoneal mucinous carcinomatosis with GNAS mutation. As stated by the investigators: “Mucinous neoplasms of the...
Outcomes With Brexucabtagene Autoleucel as Standard Therapy for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
In an analysis reported in the Journal of Clinical Oncology, Roloff et al found that use of brexucabtagene autoleucel as standard therapy in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) was associated with a high rate of measurable residual disease (MRD)-negative...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported in the Journal of Clinical Oncology by Galsky et al, extended follow-up of the phase III CheckMate 274 trial supported the efficacy of adjuvant nivolumab in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical resection. Study Details In the...
Addition of Lenvatinib to Ifosfamide/Etoposide in Children and Young Adults With Relapsed Osteosarcoma
In a phase II study (OLIE) reported in JAMA Oncology, Gaspar et al found that the addition of lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma. Study Details In the global open-label...
Addition of Cadonilimab to Platinum-Based Chemotherapy With or Without Bevacizumab in Cervical Cancer
In interim analyses of a Chinese phase III trial (COMPASSION-16) reported in The Lancet, Wu et al found that the addition of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, to platinum-based chemotherapy with or without bevacizumab significantly improved progression-free and overall...
Distant Recurrence Risk Among Women With Early Breast Cancer Enrolled in Clinical Trials Between 1990 and 2009: EBCTCG Analysis
In an analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported in The Lancet, Hills et al found that risk of distant recurrence declined over time among women with early breast cancer enrolled in clinical trials between 1990 and 2009. Study Details The pooled analysis...
Association Between Pathologic Response and Relapse-Free Survival With Neoadjuvant Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
In an analysis reported in The Lancet Oncology, D’Alessio et al found that major pathologic response and complete pathologic response to neoadjuvant immune checkpoint inhibitor therapy was associated with improved relapse-free survival in patients with hepatocellular carcinoma. Study Details The...
Addition of Induction Chemotherapy to Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer. Study Details In the open-label trial,...
SBRT vs Conventional Radiotherapy for Localized Prostate Cancer
As reported in The New England Journal of Medicine by van As et al, the phase III PACE-B trial has shown noninferiority of stereotactic body radiotherapy (SBRT) vs conventionally fractionated radiotherapy in biochemical or clinical failure in patients with low- to intermediate-risk localized...
Impact of Hormonal Contraception on Breast Cancer Risk in BRCA1 and BRCA2 Germline Mutation Carriers
In a study reported in the Journal of Clinical Oncology, Phillips et al found that carriers of BRCA1—but not BRCA2—germline mutations who used hormonal contraception were at increased risk for developing breast cancer. Study Details The investigators used pooled data from four prospective cohort...
Risk of Subsequent Neoplasms in Survivors of Childhood Neuroblastoma
In a Dutch study reported in the Journal of Clinical Oncology, Westerveld et al identified long-term risks of subsequent neoplasms in 5-year survivors of childhood neuroblastoma. Study Details The study included data from 563 survivors in the Dutch Childhood Cancer Survivor Study–LATER cohort...
Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC). Study Details In the multicenter trial, 46...
